Boehringer Ingelheim Vetmedica Gmbh

Other

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Pharma Kg

Medac Gesellschaft Fur Klinische Spezialpraparate

Bernd Kruss

Martin Andreas Folger

Stefan Henke

Bernhard Hassel

Robert Becker

Axel Prox

Klaus Daneck

Jean Marie Stassen

Hans-Juergen Kroff

Rainer H Muller

Annerose Mauz

Leonhard Schilk

Klaus Wagner

Claus Veit

Katrin Peters

Christine Votteler

Hans-Jurgen Kroff

Karin Ruehr

Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The formulation according to the invention has a shelf-life of up to 24 months or more.

Highly concentrated stable meloxicam solutions

Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The solution is for treating a mammal suffering from one or more of pain, inflammation, fever, acute mastitis, diarrhea, lameness, locomotor deficiency, or respiratory illness.

The invention relates to new formulations for improving the local tolerance of intravenously administered 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine or one of the pharmacologically acceptable acid addition salts thereof.

Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration

The invention relates to a new formulation containing Bill 890 or one of the pharmaceutically acceptable salts thereof for parenteral administration.

Formulation for the parenteral application of a sodium channel blocker

Pharmaceutical nanosuspensions for medicament administration as systems

Stable, dosage forms of .alpha.-interferons, particularly alpha-2-interferon, are described, which comprise a non-lyophilized dry film of acid-stabilized .alpha.-interferons, e.g. alpha-2-interferon, on inert carriers.

Stable alpha-interferon dosage forms

Growing community of inventors

Hochdorf, Germany

Bernd Kruss